Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
9 hedge funds and large institutions have $97.3K invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
25% less funds holding
Funds holding: 12 → 9 (-3)
35% less capital invested
Capital invested by funds: $151K → $97.3K (-$53.4K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.97K |
| 2 |
VFA
Values First Advisors
Gray,
Tennessee
|
+$921 |
| 3 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$21 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$29.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$20.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.3K |
| 4 |
Renaissance Technologies
New York
|
-$794 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$346 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
1
Values First Advisors
Gray,
Tennessee
| $41.2K | +$921 | +580 | +2% |
|
|
2
Renaissance Technologies
New York
| $35K | -$794 | -500 | -2% |
|
|
AWM
3
Activest Wealth Management
Aventure,
Florida
| $9.76K | +$21 | +13 | New |
|
|
4
Morgan Stanley
New York
| $8.08K | +$1.97K | +1,243 | +30% |
|
5
Osaic Holdings
Scottsdale,
Arizona
| $3.12K | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $127 | – | – | – |
|
7
Wells Fargo
San Francisco,
California
| $60 | – | – | – |
|
|
AA
8
Addison Advisors
Middlebury,
Vermont
| $13 | – | – | – |
|
|
FLSM
9
Frazier Life Sciences Management
Palo Alto,
California
| – | -$29.7K | -17,025 | Closed |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$20.1K | -11,607 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$2.3K | -1,315 | Closed |
|
|
12
Fidelity Investments
Boston,
Massachusetts
| – | -$346 | -200 | Closed |
|
|
13
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$3 | +2 | +10% |
|
NBRV Hedge Fund Activity: Q2 2023 in Review
9 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q2 2023, worth a combined $97.3K — down 35% from $151K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NBRV and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $1.97K. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $29.7K sold.
- 9 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q2 2023, down from 12 in Q1 2023.
- Funds reported $97.3K of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q2 2023, down 35% quarter-over-quarter.
- 1 fund opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q2 2023 and 4 closed out, a net change of -3 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q2 2023 was Morgan Stanley, an estimated $1.97K added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q2 2023 was Frazier Life Sciences Management, an estimated $29.7K sold.
Based on aggregated 13F filings for Q2 2023.